HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Recordati’s OTC Sales Lifted by Acquisitions And Italy

Executive Summary

Italy's Recordati enjoyed strong growth in its home market and abroad, lifting OTC group sales in 2019.

You may also be interested in...



EMA Reviewing Two Centralised Switch Applications

Teva's Ratiopharm and Italy's Recordati have submitted applications to switch drugs from prescription-to-OTC status through EMA's centralised procedure. Given only four products have been switched centrally to date, a double reclassification would be unprecedented. 

Italy's Recordati Takes Slice of French OTC Market With Laboratoires Tonipharm

Recordati's new private-equity owners make their first move to strengthen the Italian firm's position in Europe's OTC market by grabbing Paris-based Laboratoires Tonipharm and its leading Ginkor brand.

Taisho Boosted By Acquisitions As Japanese Business Struggles

Acquiring France's UPSA helped to lift Taisho's sales in the 12 months ended 31 March 2020, as its domestic Japanese business faltered.

Topics

Related Companies

UsernamePublicRestriction

Register

PS142249

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel